ReviewThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2012
Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.
Review in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06253559 (Clinical and Pathological Characteristics of Women With Ovarian Cancers, A National, Retrospective Cross-Sectional Study in Syria During the War), which is not on this map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical and Pathological Characteristics of Women With Ovarian Cancers, A National, Retrospective Cross-Sectional Study in Syria During the War
Who cites it
69 citing papers in PubMed, 182 citations in OpenAlex.
- Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy.Cancer gene therapy · 2022Trial
- [Total and regional fat-to-muscle mass ratio and risk of incident benign ovarian neoplasm].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Multi-Omics and Single-Cell Dissection Reveals EXT1 as a Glycosylation-Linked Therapeutic Target in Cancer.Oncology research · 2026Article
- Breast and ovarian cancers: toward a multi-cancer early detection test.Frontiers in immunology · 2026Article
- Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer.JNCI cancer spectrum · 2025Article
- Explainable Machine Learning for the Early Clinical Detection of Ovarian Cancer Using Contrastive Explanations.Journal of clinical medicine · 2025Article
- Utilizing Serum-Derived Lipidomics with Protein Biomarkers and Machine Learning for Early Detection of Ovarian Cancer in the Symptomatic Population.Cancer research communications · 2025Article
- Functional and therapeutic significant of heat-shock protein 90 (HSP90) in reproductive cancers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Awareness about the symptoms & risk factors of ovarian cancer among women in North Urban Bengaluru: A cross-sectional study.The Indian journal of medical research · 2025Article
- The effect of waiting time on ovarian cancer survival in oncology centres, Addis Ababa, Ethiopia: a retrospective cohort study.BMC women's health · 2025Article
- Review
- Glycosaminoglycan modifications of betaglycan regulate ectodomain shedding to fine-tune TGF-β signaling responses in ovarian cancer.Cell communication and signaling : CCS · 2024Article
- N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation.Molecular cancer · 2024Article
- PLGA-PEG-c(RGDfK)-IET nanobiotechnology · 2024Article
- Metabolic pathways of potential miRNA biomarkers derived from liquid biopsy in epithelial ovarian cancer.Oncology letters · 2023Article
- Clinicopathological Parameters Associated With Peritoneal Involvement in Epithelial Ovarian Tumors.Cureus · 2023Article
- Heparan sulfate proteoglycans in cancer: Pathogenesis and therapeutic potential.Advances in cancer research · 2023Article
- Guttiferone BL from the Fruits ofBioMed research international · 2023Article
- Conditional ablation of heparan sulfate expression in stromal fibroblasts promotes tumor growth in vivo.PloS one · 2023Article
- Regulation of stem cell fate by HSPGs: implication in hair follicle cycling.NPJ Regenerative medicine · 2022Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor markers are widely used in pathology not only for diagnostic purposes but also to assess the prognosis and to predict the treatment of the tumor. Because tumor marker levels may change over time, it is important to get a better understanding of the molecular changes during tumor progression. Occurrence of breast and ovarian cancer is high in older women. Common known risk factors of developing these cancers in addition to age are not having children or having children at a later age, the use of hormone replacement therapy, and mutations in certain genes. In addition, women with a history of breast cancer may also develop ovarian cancer. Here, the authors review the different tumor markers of breast and ovarian carcinoma and discuss the expression, mutations, and possible roles of cell surface heparan sulfate proteoglycans during tumorigenesis of these carcinomas. The focus is on two groups of proteoglycans, the transmembrane syndecans and the lipid-anchored glypicans. Both families of proteoglycans have been implicated in cellular responses to growth factors and morphogens, including many now associated with tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.